Heiko Lickert
@heikolickert.bsky.social
2.3K followers
1.5K following
43 posts
Developmental, stem cell and islet biologist, Professor for Beta Cell Biology @ Technical University Munich, Director of Institute for Diabetes and Regeneration Research @HelmholtzMunich
Posts
Media
Videos
Starter Packs
Pinned
Heiko Lickert
@heikolickert.bsky.social
· Nov 25
Inceptor binds to and directs insulin towards lysosomal degradation in β cells - Nature Metabolism
The insulin inhibitory receptor (inceptor) is found to bind to insulin and to regulate insulin stores by directing proinsulin and insulin towards lysosomal degradation.
doi.org
Heiko Lickert
@heikolickert.bsky.social
· Aug 26
Reposted by Heiko Lickert
Reposted by Heiko Lickert
Heiko Lickert
@heikolickert.bsky.social
· Mar 15
Heiko Lickert
@heikolickert.bsky.social
· Mar 14
Reposted by Heiko Lickert
Eunhee Choi
@eunheechoilab.bsky.social
· Feb 10
Heiko Lickert
@heikolickert.bsky.social
· Feb 22
Heiko Lickert
@heikolickert.bsky.social
· Feb 21
Heiko Lickert
@heikolickert.bsky.social
· Jan 21
Liver and pancreas in metabolic disease: from pathways to therapies
The liver and pancreas arise from a common developmental origin and are controlled by shared gene regulatory programs.These organs are central to two of the most common and devastating metabolic dise…
meetings.embo.org
Heiko Lickert
@heikolickert.bsky.social
· Jan 23
Fabian Theis
@fabiantheis.bsky.social
· Jan 22
Mapping cells through time and space with moscot - Nature
Moscot is an optimal transport approach that overcomes current limitations of similar methods to enable multimodal, scalable and consistent single-cell analyses of datasets across spatial and temporal...
www.nature.com
Heiko Lickert
@heikolickert.bsky.social
· Jan 21
Liver and pancreas in metabolic disease: from pathways to therapies
The liver and pancreas arise from a common developmental origin and are controlled by shared gene regulatory programs.These organs are central to two of the most common and devastating metabolic dise…
meetings.embo.org
Reposted by Heiko Lickert
Reposted by Heiko Lickert
Benoit Bruneau
@benoitbruneau.bsky.social
· Jan 13
Reposted by Heiko Lickert
studerl.bsky.social
@studerl.bsky.social
· Jan 13
BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial - BlueRock Therapeutics LP
BlueRock will initiate a Phase III clinical trial for bemdaneprocel, its investigational cell therapy for Parkinson’s disease. It is expected to begin in the first half of 2025 and will represent a si...
www.bluerocktx.com
Reposted by Heiko Lickert
Heiko Lickert
@heikolickert.bsky.social
· Dec 23
Reposted by Heiko Lickert
Jorge Ferrer
@jorge-ferrer.bsky.social
· Dec 21
Liver and pancreas in metabolic disease: from pathways to therapies
The liver and pancreas arise from a common developmental origin and are controlled by shared gene regulatory programs.These organs are central to two of the most common and devastating metabolic dise…
meetings.embo.org
Heiko Lickert
@heikolickert.bsky.social
· Dec 19
Liver and pancreas in metabolic disease: from pathways to therapies
The liver and pancreas arise from a common developmental origin and are controlled by shared gene regulatory programs.These organs are central to two of the most common and devastating metabolic dise…
meetings.embo.org
Heiko Lickert
@heikolickert.bsky.social
· Dec 17